Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News
SYS-CON.TV
Cloud Expo & Virtualization 2009 East
PLATINUM SPONSORS:
IBM
Smarter Business Solutions Through Dynamic Infrastructure
IBM
Smarter Insights: How the CIO Becomes a Hero Again
Microsoft
Windows Azure
GOLD SPONSORS:
Appsense
Why VDI?
CA
Maximizing the Business Value of Virtualization in Enterprise and Cloud Computing Environments
ExactTarget
Messaging in the Cloud - Email, SMS and Voice
Freedom OSS
Stairway to the Cloud
Sun
Sun's Incubation Platform: Helping Startups Serve the Enterprise
POWER PANELS:
Cloud Computing & Enterprise IT: Cost & Operational Benefits
How and Why is a Flexible IT Infrastructure the Key To the Future?
Click For 2008 West
Event Webcasts
Global Anticoagulants Industry

NEW YORK, Dec. 5, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

 

Global Anticoagulants Industry

http://www.reportlinker.com/p098261/Global-Anticoagulants-Industry.html#...

 

This report analyzes the worldwide markets for Anticoagulants in Millions of US$ by the following Product Segments: Oral Anticoagulants, and Injectable Anticoagulants (Unfractionated Heparin, and Low Molecular Weight Heparin). The report provides separate comprehensive analytics for the US, Japan, Europe and Rest of World. Annual estimates and forecastsare provided for the period of 2010 through 2018. A six-year historic analysis is also provided for these markets. The report profiles 45 companies including many key and niche players such as Bayer Healthcare AG, Boehringer Ingelheim, Bristol-Myers Squibb Company, Eisai Inc., GlaxoSmithKline plc, LEO Pharmaceutical Products, Mitsubishi Tanabe Pharma Corporation, Pfizer Inc., and Sanofi, Teva Pharmaceutical Industries Ltd., and Teva Pharmaceuticals USA. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

 

 

 

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-2

Quantitative Techniques & Analytics I-2

Product Definitions And Scope of Study I-3

 

 

II. EXECUTIVE SUMMARY

 

1. OUTLOOK II-1

A Prelude II-1

Anticoagulants- An Evolving Market II-1

Injectables or Oral Drugs - The Road Ahead II-2

Conventional Oral Drugs to Face the Heat Too II-2

New Drugs yet to Gain Mainstream Status II-2

Sizing the Market II-3

 

2. INDUSTRY OVERVIEW II-4

Issues with Traditional Drugs Fueling the Hunt for New

Anticoagulants II-4

New Therapies: Need of the Hour II-4

Drug Advancements Drive Anticoagulant Market II-4

Niche Markets - The New Target for Drug Makers II-4

Anticoagulant Therapy in IPF: Reduces Mortality Risk II-5

Anticoagulants to Lose UA/AMI Markets to Antiplatelets II-5

An Opportunity to Grow Further II-5

Warfarin & Heparins: The Former Market Leaders II-5

Generics Drugs Prevail in the Anticoagulant Market II-6

Concern Over Underutilization of Warfarin II-6

Novel Oral Anticoagulants to Turbo-Charge Market Growth II-7

Hurdles Exist for New Oral Agents II-7

The Merits and Demerits of New Age Anticoagulants II-7

Lack of Adequate Trials Mar Pediatric Anticoagulants Market II-8

Improved Anticoagulant Agents for Children Group II-8

Growing Demand for Self-Testing II-8

LMWHs Ease Outpatient Management II-8

Novel Heparins Enhance Market Potential II-9

A Focus on Failed or Withdrawn Agents in Recent Past II-9

Idraparinux and Idrabiotaparinux Sodium - Sanofi's

Discontinued Agents II-9

Lack of Statistical Significance Leads to Culmination of

Tecarfarin's Development II-10

Sofigatran - A Failed Agent from Mitsubishi Tanabe Pharma II-10

 

3. ORAL ANTICOAGULANT AGENTS II-11

Traditional Oral Anticoagulants II-11

Warfarin II-11

Advantages and Alternatives II-11

Side Effects II-11

Limitations II-12

Coumadin - The Branded Warfarin II-12

Novel Oral Anticoagulants II-12

Dabigatran Etexilate (Pradaxa) II-12

Table 1: Pradaxa and Warfarin - A Comparative Study II-13

Approved Indications for Pradaxa in Select Regions II-13

Rivaroxaban (Xarelto) II-13

Approved Indications for Xarelto in Select Regions II-14

Xarelto Patent Expiration in Various Regions II-14

Apixaban (Eliquis) II-15

Betrixaban II-15

Comparison of Select Approved and Pipeline Anticoagulant

Agents in a Nutshell II-15

Market Dynamics II-16

New Oral Drugs More Efficacious In Reducing Stroke II-16

New Generation Anticoagulants Enter the Market, Warfarin

Comes Under Pressure II-16

Oral Anticoagulants Market to Witness Intense Competition II-16

Pradaxa- A High Potential Replacement to Warfarin II-17

Packaging May Hurt Pradaxa's Prospects II-17

New Oral Drugs in Various Indications II-17

Emerging Targets in the Anticoagulation Space II-18

Daiichi Sankyo Upbeat on Prospects of Edoxaban II-18

ELIQUIS' FDA Approval Faces Further Delays II-19

The ARISTOTLE Trial II-19

Eliquis - More Promising than Existing Oral Anticoagulants II-20

Competitors Capitalize on Delay in Eliquis' Approval II-20

Do New Oral Anticoagulants Circumvent Issues with

Conventional Drugs? II-20

Hemostatic Agents for Reversing Action of New Oral Drugs - An

Area Demanding Active Research II-21

 

4. INJECTABLE ANTICOAGULANTS II-22

Injectable Anticoagulants- An Insight II-22

Heparin - The Back Bone of Injectable Anticoagulants II-22

Unfractionated Heparin II-22

Advantages and Alternatives II-23

Limitations II-23

Low Molecular Weight Heparins II-23

Indications II-24

Advantages II-24

Contraindications II-25

Side Effects II-25

Caution II-25

Costs II-25

Impediments II-25

A Focus on Select Heparin Based Injectables II-26

Lovenox/Clexane (enoxaparin) II-26

Approved Indications for Lovenox II-26

Advantages and Alternatives II-26

Table 2: World Lovenox Sales by Geographic Region

(2009-2011): Breakdown of Value Sales in US$ Million for

Western Europe, US, Emerging Markets and Others (includes

corresponding Graph/Chart) II-27

Fragmin (dalteparin sodium) II-27

Approved Indications for Fragmin Use II-28

Contraindications II-28

Precautions II-29

Fraxiparine (nadroparin) II-29

Innohep (tinzaparin) II-29

Contraindications II-30

Side Effects II-30

Other Serious Adverse Events Associated with Innohep II-31

Precautions II-31

Normiflo (ardeparin) II-31

Clivarine (reviparin) II-32

Table 3: Summary of Available LMWHs II-32

A Comparison of FDA Approved Indications for Select Injectable

LMWHs - Lovenox, Innohep and Fragmin II-33

Non-Heparin Anticoagulant Injectables - An Overview II-33

Arixtra (fondaparinux) II-33

Contraindications II-34

Market and Market Participants II-34

Angiomax (bivalirudin) II-34

Advantages II-35

Contraindications II-35

Side Effects II-35

Argatroban/Novastan II-35

Side Effects II-36

Precautions II-36

Refludan (lepirudin) II-36

Orgaran (danaparoid Sodium) II-37

Contraindications II-37

Side Effects II-38

Caution II-38

Precaution II-38

A Comparative Analysis of Various Direct Thrombin Inhibitors II-38

 

5. A COMPARATIVE STUDY OF ANTICOAGULANT THERAPIES II-39

A Comparative Study of Warfarin Against LMWHs II-39

A Comparative Study of LMWH Against UFH II-40

A Comparative Study of New Anticoagulants/ Anticoagulant

Candidates Against Warfarin II-41

A Comparative Study of Heparin Against Angiomax II-41

A Comparative Study of Arixtra Against UFH and LMWH II-41

A Comparative Study of Angiomax Against UFH and LMWH II-41

 

6. AREAS OF INDICATION II-42

Indications for Anticoagulant Use II-42

Venous/DVT Thrombosis Indications II-42

Desired Anticoagulant Qualities for DVT Indications II-42

Venous Thromboembolism II-42

Deep Vein Thrombosis II-42

Pulmonary Embolism II-44

Orthopedic (Hip or Knee Replacement) Surgery II-45

General Surgery II-46

Cancer II-46

Arterial Thrombosis Indications II-47

Arterial Thrombosis II-47

Acute Coronary Syndromes II-47

Atrial Fibrillation II-48

Unstable Angina II-49

List of Approved Anticoagulants for Unstable Angina II-50

Myocardial Infraction II-50

Non ST-Segment Elevation MI II-50

List of Approved Anticoagulants for Non-ST Segment

Elevation Myocardial Infarction II-51

Percutaneous Transluminal Coronary Angioplasty (PTCA) II-51

List of Approved Anticoagulants for Angioplasty Procedures II-52

Heparin Induced Thrombocytopenia (HIT) Indications II-52

HIT Type I II-52

HIT Type II II-52

Heparin Induced Thrombocytopenia with Thrombosis (HITTS) II-54

Other Indications II-54

Hemodialysis II-54

 

7. DRUG DEVELOPMENT PIPELINE II-55

Select Anticoagulants in Clinical Development II-55

Anticoagulant Therapies in Development Stage II-56

Idraparinux - Sanofi II-56

0673 - Sanofi II-56

MER-102 II-56

Semuloparin Sodium (AVE 5026) II-56

 

8. PRODUCT INTRODUCTIONS/APPROVALS II-57

Mitsubishi Pharma Introduces Argatroban in the UK II-57

Bayer Obtains Canadian Approval for Xarelto in the Treatment

of Deep Vein Thrombosis II-57

Pradaxa Gains Regulatory Approval in Japan for Prevention of

Stroke II-57

Pfizer and Bristol-Myers Launch ELIQUIS Black Triangle Drug II-57

ELIQUIS® Receives Approval in EU in Prevention of VTE II-58

Xarelto Obtains Approval in UK II-58

Xarelto Receives FDA Approval for Prevention of DVT II-58

Eisai Launches Warfarin Granules 0.2% in Japan II-58

Amphastar Receives FDA Approval for ANDA of Enoxaparin Sodium

Injection II-58

Boehringer Ingelheim Obtains EU Approval for Pradaxa in AF II-59

Daiichi Sankyo Introduces Edoxaban Tablets in Japan II-59

 

9. PRODUCT INTRODUCTIONS/APPROVALS IN RECENT PAST- A PERSPECTIVE

BUILDER II-60

GSK Receives EU Approval for Arixtra® II-60

Pradaxa Receives FDA Approval II-60

Canyon Pharmaceuticals Introduces Iprivask II-60

Teva Receives FDA's Tentative Approval for Argatroban II-60

TrimGen Receives FDA 510(k) Approval for Marketing eQ-PCR™ LC

Warfarin Genotyping Kit II-61

Lundbeck Launches ATryn® Commercially in the US II-61

The Medicines Co Receives European Approval for Angiox (

Bivalirudin) II-61

 

10. RECENT INDUSTRY ACTIVITY II-62

FDA Issues Complete Response Letter for Eliquis's New Drug

Application II-62

FDA Issues Complete Response Letter to Rivaroxaban's (Xarelto)

NDA for ACS II-62

US FDA Extends Date for Eliquis' New Drug Application II-62

Pradaxa® Receives NICE Recommendation II-62

BioInvent and ThromboGenics Discontinue Development of TB-402 II-62

Watson Receives Stay Order on Preliminary Injunction II-63

FDA Assigns Priority Review for Xarelto Supplemental NDA II-63

Portola Pharmaceuticals Re-Acquires Rights to Betrixaban II-63

FDA Accepts New Drug Application for ELIQUIS® II-63

Astellas Pharma Halts Development of Anticoagulant II-63

Sanofi-Aventis Changes Name to Sanofi II-63

 

11. CORPORATE ACTIVITY IN RECENT PAST - A PERSPECTIVE BUILDER II-64

Boehringer Ingelheim Expands Manufacturing Capacity at Ingelheim II-64

Sagent Pharmaceuticals Secures FDA Approval for Heparin Sodium

Injection II-64

Biomet Acquires Cytosol Laboratories II-64

Portola Inks $470 M Agreement with Merck for Phase II

Anticoagulant II-64

Catalent Pharma Inks Strategic Alliance Deal with Endotis Pharma II-65

Nuvelo and ARCA biopharma Merge II-65

 

12. FOCUS ON SELECT GLOBAL PLAYERS II-66

Bayer Healthcare AG (Germany) II-66

Boehringer Ingelheim (Germany) II-66

Bristol-Myers Squibb Company (USA) II-66

Eisai Inc. (USA) II-67

GlaxoSmithKline plc (UK) II-67

LEO Pharmaceutical Products (Denmark) II-67

Mitsubishi Tanabe Pharma Corporation (Japan) II-68

Pfizer Inc. (USA) II-68

Sanofi (France) II-68

Teva Pharmaceutical Industries Ltd (Israel) II-69

Teva Pharmaceuticals USA (USA) II-69

 

13. GLOBAL MARKET PERSPECTIVE II-70

Table 4: World Recent Past, Current & Future Analysis for

Anticoagulants by Geographic Region/Country - US, Japan,

Europe, and Rest of World Markets Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2010 through

2018 (includes corresponding Graph/Chart) II-70

 

Table 5: World Historic Review for Anticoagulants by

Geographic Region/Country - US, Japan, Europe, and Rest of

World Markets Independently Analyzed with Annual Sales Figures

in US$ Million for Years 2004 through 2009 (includes

corresponding Graph/Chart) II-71

 

Table 6: World 15-Year Perspective for Anticoagulants by

Geographic Region/Country - Percentage Breakdown of Dollar

Sales for US, Japan, Europe, and Rest of World Markets for

Years 2004, 2011 & 2018 (includes corresponding Graph/Chart) II-72

 

Table 7: World Recent Past, Current & Future Analysis for Oral

Anticoagulants by Geographic Region/Country - US, Japan,

Europe, and Rest of World Markets Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2010 through

2018 (includes corresponding Graph/Chart) II-73

 

Table 8: World Historic Review for Oral Anticoagulants by

Geographic Region/ Country - US, Japan, Europe, and Rest of

World Markets Independently Analyzed with Annual Sales Figures

in US$ Million for Years 2004 through 2009 (includes

corresponding Graph/Chart) II-74

 

Table 9: World 15-Year Perspective for Oral Anticoagulants by

Geographic Region/Country - Percentage Breakdown of Dollar

Sales for US, Japan, Europe, and Rest of World Markets for

Years 2004, 2011 & 2018 (includes corresponding Graph/Chart) II-75

 

Table 10: World Recent Past, Current & Future Analysis for

Injectable Anticoagulants by Geographic Region/Country - US,

Japan, Europe, and Rest of World Markets Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2010 through 2018 (includes corresponding Graph/Chart) II-76

 

Table 11: World Historic Review for Injectable Anticoagulants

by Geographic Region/ Country - US, Japan, Europe, and Rest of

World Markets Independently Analyzed with Annual Sales Figures

in US$ Million for Years 2004 through 2009 (includes

corresponding Graph/Chart) II-77

 

Table 12: World 15-Year Perspective for Injectable

Anticoagulants by Geographic Region/Country - Percentage

Breakdown of Dollar Sales for US, Japan, Europe, and Rest of

World Markets for Years 2004, 2011 & 2018 (includes

corresponding Graph/Chart) II-78

 

Table 13: World Recent Past, Current & Future Analysis for

Injectable Anticoagulants by Product Segment - Unfractionated

Heparin and Low Molecular Weight Heparin Markets Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2010 through 2018 (includes corresponding Graph/Chart) II-79

 

Table 14: World Historic Review for Injectable Anticoagulants

by Product Segment - Unfractionated Heparin and Low Molecular

Weight Heparin Markets Independently Analyzed with Annual

Sales Figures in US$ Million for Years 2004 through 2009

(includes corresponding Graph/Chart) II-80

 

Table 15: World 15-Year Perspective for Injectable

Anticoagulants by Product Segment - Percentage Breakdown of

Dollar Sales for Unfractionated Heparin and Low Molecular

Weight Heparin Markets Independently Analyzed for Years 2004,

2011 & 2018 (includes corresponding Graph/Chart) II-81

 

Table 16: World Recent Past, Current & Future Analysis for

Unfractionated Heparin by Geographic Region/Country - US,

Japan, Europe, and Rest of World Markets Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2010 through 2018 (includes corresponding Graph/Chart) II-82

 

Table 17: World Historic Review for Unfractionated Heparin by

Geographic Region/Country - US, Japan, Europe, and Rest of

World Markets Independently Analyzed with Annual Sales Figures

in US$ Million for Years 2004 through 2009 (includes

corresponding Graph/Chart) II-83

 

Table 18: World 15-Year Perspective for Unfractionated Heparin

by Geographic Region/ Country - Percentage Breakdown of Dollar

Sales for US, Japan, Europe, and Rest of World Markets for

Years 2004, 2011 & 2018 (includes corresponding Graph/Chart) II-84

 

Table 19: World Recent Past, Current & Future Analysis for Low

Molecular Weight Heparin by Geographic Region/Country - US,

Japan, Europe, and Rest of World Markets Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2010 through 2018 (includes corresponding Graph/Chart) II-85

 

Table 20: World Historic Review for Low Molecular Weight

Heparin by Geographic Region/Country - US, Japan, Europe, and

Rest of World Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2004 through 2009 (includes

corresponding Graph/Chart) II-86

 

Table 21: World 15-Year Perspective for Low Molecular Weight

Heparin by Geographic Region/Country - Percentage Breakdown of

Dollar Sales for US, Japan, Europe, and Rest of World Markets

for Years 2004, 2011 & 2018 (includes corresponding

Graph/Chart) II-87

 

 

III. MARKET

 

1. THE UNITED STATES III-1

A.Market Analysis III-1

Outlook III-1

Atrial Fibrillation - A Key Risk Factor III-1

Price Controls III-1

US Anticoagulants Market III-2

FDA Approved Anticoagulants III-2

Table 22: Novel Drugs/Drug Candidates in the US

Anticoagulants Market III-3

Table 23: US Vitamin K Antagonists Market (2011):

Percentage Breakdown of Value Sales by Drug- Coumadin,

Warfarin Generics and Others (includes corresponding

Graph/Chart) III-3

 

Table 24: US Direct Thrombin (II) Inhibitors Market (2011):

Percentage Breakdown of Value Sales by Drug - Pradaxa,

Angiomax, Argatroban, Refludan and Others (includes

corresponding Graph/Chart) III-3

 

Table 25: US Market for Xarelto (2011): Percentage Share

Breakdown of Sales by Indication- Atrial Fibrillation and

DVT Prevention in Surgery (includes corresponding

Graph/Chart) III-4

Payers Keen on New Therapies III-4

Pradaxa's Initial Performance Commendable, Conventional AVK

Products Still Dominate III-4

US Heparin Market III-5

Hinging on Market Opportunities III-5

Generics - Threatening Branded Anticoagulants III-5

List of Patent Protected Anticoagulants in the US III-6

Generic Competition Threatens Sanofi's Lovenox III-6

Table 26: Leading Players in the US Enoxaparin Sodium

Market (2011): Percentage Breakdown of Sales for Sandoz and

Sanofi (includes corresponding Graph/Chart) III-6

 

Table 27: US Enoxaparin Sodium Market by Sector (2011):

Percentage Breakdown of Sales for Institutional and Retail

Sectors (includes corresponding Graph/Chart) III-6

Ignorance - A Major Hindrance III-7

Future Challenges and Growth Drivers III-7

US Emerging Anticoagulant Market III-7

Product Introductions/Approvals III-8

Recent Industry Activity III-8

Focus on Select Players III-10

B.Market Analytics III-12

Table 28: US Recent Past, Current & Future Analysis for

Anticoagulants by Product Segment - Oral Anticoagulants and

Injectable Anticoagulants (Unfractionated Heparin and Low

Molecular Weight Heparin) Markets Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2010

through 2018 (includes corresponding Graph/Chart) III-12

 

Table 29: US Historic Review for Anticoagulants by Product

Segment - Oral Anticoagulants and Injectable Anticoagulants

(Unfractionated Heparin and Low Molecular Weight Heparin)

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2004 through 2009 (includes

corresponding Graph/Chart) III-13

 

Table 30: US 15-Year Perspective for Anticoagulants by

Product Segment - Percentage Breakdown of Dollar Sales for

Oral Anticoagulants and Injectable Anticoagulants

(Unfractionated Heparin and Low Molecular Weight Heparin)

Markets for the Years 2004, 2011 & 2018 (includes

corresponding Graph/Chart) III-14

 

2. JAPAN III-15

A.Market Analysis III-15

Outlook III-15

Anticoagulants Market in Japan III-15

Rising Incidence of Pulmonary Thromboembolism III-15

Product Introductions/Approvals III-15

Recent Industry Activity III-16

Focus on Select Players III-16

Regional Player III-17

B.Market Analytics III-18

Table 31: Japanese Recent Past, Current & Future Analysis

for Anticoagulants by Product Segment - Oral Anticoagulants

and Injectable Anticoagulants (Unfractionated Heparin and

Low Molecular Weight Heparin) Markets Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2010

through 2018 (includes corresponding Graph/Chart) III-18

 

Table 32: Japanese Historic Review for Anticoagulants by

Product Segment - Oral Anticoagulants and Injectable

Anticoagulants (Unfractionated Heparin and Low Molecular

Weight Heparin) Markets Independently Analyzed with Annual

Sales Figures in US$ Million for Years 2004 through 2009

(includes corresponding Graph/Chart) III-19

 

Table 33: Japanese 15-Year Perspective for Anticoagulants by

Product Segment - Percentage Breakdown of Dollar Sales for

Oral Anticoagulants and Injectable Anticoagulants

(Unfractionated Heparin and Low Molecular Weight Heparin)

Markets for the Years 2004, 2011 & 2018 (includes

corresponding Graph/Chart) III-20

 

3. EUROPE III-21

A.Market Analysis III-21

Outlook III-21

Market in High Need of an Ideal Therapy III-21

Product Introductions/Approvals III-21

B.Market Analytics III-23

Table 34: European Recent Past, Current & Future Analysis

for Anticoagulants by Geographic Region/Country - France,

Germany, Italy, UK, Spain, and Rest of Europe Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2010 through 2018 (includes corresponding

Graph/Chart) III-23

 

Table 35: European Historic Review for Anticoagulants by

Geographic Region / Country - France, Germany, Italy, UK,

Spain, and Rest of Europe Markets Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2004

through 2009 (includes corresponding Graph/Chart) III-24

 

Table 36: European 15-Year Perspective for Anticoagulants by

Geographic Region - Percentage Breakdown of Dollar Sales for

France, Germany, Italy, UK, Spain, and Rest of Europe

Markets for Years 2004, 2011 & 2018 (includes corresponding

Graph/Chart) III-25

 

Table 37: European Recent Past, Current & Future Analysis

for Anticoagulants by Product Segment - Oral Anticoagulants

and Injectable Anticoagulants (Unfractionated Heparin and

Low Molecular Weight Heparin) Markets Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2010

through 2018 (includes corresponding Graph/Chart) III-26

 

Table 38: European Historic Review for Anticoagulants by

Product Segment - Oral Anticoagulants and Injectable

Anticoagulants (Unfractionated Heparin and Low Molecular

Weight Heparin) Markets Independently Analyzed with Annual

Sales Figures in US$ Million for Years 2004 through 2009

(includes corresponding Graph/Chart) III-27

 

Table 39: European 15-Year Perspective for Anticoagulants by

Product Segment - Percentage Breakdown of Dollar Sales for

Oral Anticoagulants and Injectable Anticoagulants

(Unfractionated Heparin and Low Molecular Weight Heparin)

Markets for the Years 2004, 2011 & 2018 (includes

corresponding Graph/Chart) III-28

 

3a. FRANCE III-29

A.Market Analysis III-29

Outlook III-29

Recent Industry Activity III-29

Focus on Select Players III-29

B.Market Analytics III-30

Table 40: French Recent Past, Current & Future Analysis for

Anticoagulants by Product Segment - Oral Anticoagulants and

Injectable Anticoagulants (Unfractionated Heparin and Low

Molecular Weight Heparin) Markets Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2010

through 2018 (includes corresponding Graph/Chart) III-30

 

Table 41: French Historic Review for Anticoagulants by

Product Segment - Oral Anticoagulants and Injectable

Anticoagulants (Unfractionated Heparin and Low Molecular

Weight Heparin) Markets Independently Analyzed with Annual

Sales Figures in US$ Million for Years 2004 through 2009

(includes corresponding Graph/Chart) III-31

 

Table 42: French 15-Year Perspective for Anticoagulants by

Product Segment - Percentage Breakdown of Dollar Sales for

Oral Anticoagulants and Injectable Anticoagulants

(Unfractionated Heparin and Low Molecular Weight Heparin)

Markets for the Years 2004, 2011 & 2018 (includes

corresponding Graph/Chart) III-32

 

3b. GERMANY III-33

A.Market Analysis III-33

Outlook III-33

Market Drivers for Injectable Anticoagulants III-33

Anticoagulants Growth Drive European POC Testing Market III-33

Focus on Select Players III-33

B.Market Analytics III-35

Table 43: German Recent Past, Current & Future Analysis for

Anticoagulants by Product Segment - Oral Anticoagulants and

Injectable Anticoagulants (Unfractionated Heparin and Low

Molecular Weight Heparin) Markets Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2010

through 2018 (includes corresponding Graph/Chart) III-35

 

Table 44: German Historic Review for Anticoagulants by

Product Segment - Oral Anticoagulants and Injectable

Anticoagulants (Unfractionated Heparin and Low Molecular

Weight Heparin) Markets Independently Analyzed with Annual

Sales Figures in US$ Million for Years 2004 through 2009

(includes corresponding Graph/Chart) III-36

 

Table 45: German 15-Year Perspective for Anticoagulants by

Product Segment - Percentage Breakdown of Dollar Sales for

Oral Anticoagulants and Injectable Anticoagulants

(Unfractionated Heparin and Low Molecular Weight Heparin)

Markets for the Years 2004, 2011 & 2018 (includes

corresponding Graph/Chart) III-37

 

3c. ITALY III-38

A.Market Analysis III-38

Outlook III-38

B.Market Analytics III-39

Table 46: Italian Recent Past, Current & Future Analysis for

Anticoagulants by Product Segment - Oral Anticoagulants and

Injectable Anticoagulants (Unfractionated Heparin and Low

Molecular Weight Heparin) Markets Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2010

through 2018 (includes corresponding Graph/Chart) III-39

 

Table 47: Italian Historic Review for Anticoagulants by

Product Segment - Oral Anticoagulants and Injectable

Anticoagulants (Unfractionated Heparin and Low Molecular

Weight Heparin) Markets Independently Analyzed with Annual

Sales Figures in US$ Million for Years 2004 through 2009

(includes corresponding Graph/Chart) III-40

 

Table 48: Italian 15-Year Perspective for Anticoagulants by

Product Segment - Percentage Breakdown of Dollar Sales for

Oral Anticoagulants and Injectable Anticoagulants

(Unfractionated Heparin and Low Molecular Weight Heparin)

Markets for the Years 2004, 2011 & 2018 (includes

corresponding Graph/Chart) III-41

 

3d. THE UNITED KINGDOM III-42

A.Market Analysis III-42

Outlook III-42

Product Introductions/Approvals III-42

Recent Industry Activity III-43

Focus on Select Players III-43

B.Market Analytics III-44

Table 49: UK Recent Past, Current & Future Analysis for

Anticoagulants by Product Segment - Oral Anticoagulants and

Injectable Anticoagulants (Unfractionated Heparin and Low

Molecular Weight Heparin) Markets Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2010

through 2018 (includes corresponding Graph/Chart) III-44

 

Table 50: UK Historic Review for Anticoagulants by Product

Segment - Oral Anticoagulants and Injectable Anticoagulants

(Unfractionated Heparin and Low Molecular Weight Heparin)

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2004 through 2009 (includes

corresponding Graph/Chart) III-45

 

Table 51: UK 15-Year Perspective for Anticoagulants by

Product Segment - Percentage Breakdown of Dollar Sales for

Oral Anticoagulants and Injectable Anticoagulants

(Unfractionated Heparin and Low Molecular Weight Heparin)

Markets for the Years 2004, 2011 & 2018 (includes

corresponding Graph/Chart) III-46

 

3e. SPAIN III-47

A.Market Analysis III-47

Outlook III-47

B.Market Analytics III-48

Table 52: Spanish Recent Past, Current & Future Analysis for

Anticoagulants by Product Segment - Oral Anticoagulants and

Injectable Anticoagulants (Unfractionated Heparin and Low

Molecular Weight Heparin) Markets Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2010

through 2018 (includes corresponding Graph/Chart) III-48

 

Table 53: Spanish Historic Review for Anticoagulants by

Product Segment - Oral Anticoagulants and Injectable

Anticoagulants (Unfractionated Heparin and Low Molecular

Weight Heparin) Markets Independently Analyzed with Annual

Sales Figures in US$ Million for Years 2004 through 2009

(includes corresponding Graph/Chart) III-49

 

Table 54: Spanish 15-Year Perspective for Anticoagulants by

Product Segment - Percentage Breakdown of Dollar Sales for

Oral Anticoagulants and Injectable Anticoagulants

(Unfractionated Heparin and Low Molecular Weight Heparin)

Markets for the Years 2004, 2011 & 2018 (includes

corresponding Graph/Chart) III-50

 

3f. REST OF EUROPE III-51

A.Market Analysis III-51

Outlook III-51

Focus on Select Player III-51

B.Market Analytics III-52

Table 55: Rest of Europe Recent Past, Current & Future

Analysis for Anticoagulants by Product Segment - Oral

Anticoagulants and Injectable Anticoagulants (Unfractionated

Heparin and Low Molecular Weight Heparin) Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2010 through 2018 (includes corresponding

Graph/Chart) III-52

 

Table 56: Rest of Europe Historic Review for Anticoagulants

by Product Segment - Oral Anticoagulants and Injectable

Anticoagulants (Unfractionated Heparin and Low Molecular

Weight Heparin) Markets Independently Analyzed with Annual

Sales Figures in US$ Million for Years 2004 through 2009

(includes corresponding Graph/Chart) III-53

 

Table 57: Rest of Europe 15-Year Perspective for

Anticoagulants by Product Segment - Percentage Breakdown of

Dollar Sales for Oral Anticoagulants and Injectable

Anticoagulants (Unfractionated Heparin and Low Molecular

Weight Heparin) Markets for the Years 2004, 2011 & 2018

(includes corresponding Graph/Chart) III-54

 

4. REST OF WORLD III-55

A.Market Analysis III-55

Outlook III-55

Heparin Market in China Gains Momentum III-55

Product Introduction/Approval III-55

Focus on Select Player III-56

B.Market Analytics III-57

Table 58: Rest of World Recent Past, Current & Future

Analysis for Anticoagulants by Product Segment - Oral

Anticoagulants and Injectable Anticoagulants (Unfractionated

Heparin and Low Molecular Weight Heparin) Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2010 through 2018 (includes corresponding

Graph/Chart) III-57

 

Table 59: Rest of World Historic Review for Anticoagulants

by Product Segment - Oral Anticoagulants and Injectable

Anticoagulants (Unfractionated Heparin and Low Molecular

Weight Heparin) Markets Independently Analyzed with Annual

Sales Figures in US$ Million for Years 2004 through 2009

(includes corresponding Graph/Chart) III-58

 

Table 60: Rest of World 15-Year Perspective for

Anticoagulants by Product Segment - Percentage Breakdown of

Dollar Sales for Oral Anticoagulants and Injectable

Anticoagulants (Unfractionated Heparin and Low Molecular

Weight Heparin) Markets for the Years 2004, 2011 & 2018

(includes corresponding Graph/Chart) III-59

 

 

IV. COMPETITIVE LANDSCAPE

 

Total Companies Profiled: 45 (including Divisions/Subsidiaries - 53)

 

The United States (24)

Canada (1)

Japan (3)

Europe (13)

- France (1)

- Germany (4)

- The United Kingdom (4)

- Rest of Europe (4)

Asia-Pacific (Excluding Japan) (11)

Latin America (1)

 

 

 

To order this report:

Drug_and_Medication Industry: Global Anticoagulants Industry

 

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

 

SOURCE Reportlinker

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Cloud Developer Stories
"We help companies that are using a lot of Software as a Service. We help companies manage and gain visibility into what people are using inside the company and decide to secure them or use standards to lock down or to embrace the adoption of SaaS inside the company," explained S...
15th Cloud Expo, which took place Nov. 4-6, 2014, at the Santa Clara Convention Center in Santa Clara, CA, expanded the conference content of @ThingsExpo, Big Data Expo, and DevOps Summit to include two developer events. IBM held a Bluemix Developer Playground on November 5 and...
Some developers believe that monitoring is a function of the operations team. Some operations teams firmly believe that monitoring the systems they maintain is sufficient to run the business successfully. Most of them are wrong. The complexity of today's applications have gone fa...
The 4th International DevOps Summit, co-located with16th International Cloud Expo – being held June 9-11, 2015, at the Javits Center in New York City, NY – announces that its Call for Papers is now open. Born out of proven success in agile development, cloud computing, and proce...
SAP is delivering break-through innovation combined with fantastic user experience powered by the market-leading in-memory technology, SAP HANA. In his General Session at 15th Cloud Expo, Thorsten Leiduck, VP ISVs & Digital Commerce, SAP, discussed how SAP and partners provide c...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021



SYS-CON Featured Whitepapers
ADS BY GOOGLE